Andras Heczey, David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy Courtney, Azlann Arnett, Julien Fleurence, Ramy Sweidan, Tao Wang, Huimin Zhang, Prakash Masand, John Maris, Dan Martinez, Jennier Pogoriler, Navin Varadarajan, Sachin Thakkar, Deborah Lyon, Natasha Lapteva, Mei Zhuyong, Kalyani Patel, Dolores Lopez-Terrada, Carlos Ramos, Premal Lulla, Tannaz Armaghany, Bambi Grilley, Gianpietro Dotti, Leonid Metelitsa, Helen Heslop, Malcolm Brenner, Pavel Sumazin
Interleukin-15 (IL15) promotes the survival of T lymphocytes and enhances the antitumor properties of CAR T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy1-4. Glypican-3 (GPC3) is expressed in a group of solid cancers5-10, and here we report the first evaluation in humans of the effects of IL15 co-expression on GPC3-CAR T cells. Cohort 1 patients (NCT02905188/NCT02932956) received GPC3-CAR T cells, which were safe but produced no objective antitumor responses and reached peak expansion at two weeks...
April 3, 2024: Research Square